CompletedPhase 2

Radiation Therapy in Treating Young Patients With Gliomas

United States, Australia, Canada92 participantsStarted 2006-11

Plain-language summary

RATIONALE: Specialized radiation therapy that delivers radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This phase II trial is studying how well radiation therapy works in treating young patients with gliomas.

Who can participate

Age range

3 Years – 20 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Histologically confirmed\* low-grade glioma, including any of the following: * Juvenile pilocytic astrocytoma (JPA) or pleomorphic JPA * Diffuse astrocytoma, including any of the following subtypes: * Fibrillary astrocytoma * Gemistocytic astrocytoma * Subependymal giant cell astrocytoma * Pleomorphic xanthoastrocytoma * Low-grade oligoastrocytoma * Low-grade oligodendroglioma * Low-grade glioma not otherwise specified NOTE: \*Patients with chiasmatic lesions who have contiguous extension of tumor into other regions of the visual pathway by CT scan or MRI are eligible without histopathologic confirmation; repeat biopsy required for patients with recurrent tumors that enhance but whose initial tumor did not * Measurable disease by radiography * Meets any of the following criteria: * Progressive nonresectable disease * Any location in the brain * Patients with a less than gross total resection are eligible provided they are symptomatic from their tumor OR the risk from neurologic impairment with progression is high enough to warrant immediate treatment * Has undergone biopsy only * Must have received ≥ 1 course of prior chemotherapy (for patients \< 10 years of age) * Prior chemotherapy optional (for patients ≥ 10 years of age) * No type-1 neurofibromatosis * No evidence of leptomeningeal dissemination PATIENT CHARACTERISTICS: Age * 3 to 20 Performance status * ECOG 0-2 OR * Karnofsky 50-100% (for patie…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Marginal-failure Rate

Timeframe: Up to 5 years

Trial details

NCT IDNCT00238264

SponsorChildren's Oncology Group

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2013-12-30

Results submitted2017-01-05

View on ClinicalTrials.gov More Brain Tumor trials

Who can participate

Age range

3 Years – 20 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.